Search

Your search keyword '"Allegretti, Andrew S."' showing total 277 results
Start Over Author "Allegretti, Andrew S."
277 results on '"Allegretti, Andrew S."'

2. Prognosis of Transplant-Ineligible Patients with Cirrhosis and Acute Kidney Injury Who Initiate Renal Replacement Therapy

Author

Diaz, Paige McLean, Saly, Danielle L., Horick, Nora, Petrosyan, Romela, Gitto, Zachary, Indriolo, Teresa, Li, Lucinda, Kahn-Boesel, Olivia, Donlan, John, Robinson, Blair, Dow, Lindsay, Liu, Annie, El-Jawahri, Areej, Parada, Xavier Vela, Combs, Sara, Teixeira, Joao, Chung, Raymond, Allegretti, Andrew S., and Ufere, Nneka N.

Published
2024
Full Text
View/download PDF

6. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting

Author

Nadim, Mitra K., Kellum, John A., Forni, Lui, Francoz, Claire, Asrani, Sumeet K., Ostermann, Marlies, Allegretti, Andrew S., Neyra, Javier A., Olson, Jody C., Piano, Salvatore, VanWagner, Lisa B., Verna, Elizabeth C., Akcan-Arikan, Ayse, Angeli, Paolo, Belcher, Justin M., Biggins, Scott W., Deep, Akash, Garcia-Tsao, Guadalupe, Genyk, Yuri S., Gines, Pere, Kamath, Patrick S., Kane-Gill, Sandra L., Kaushik, Manish, Lumlertgul, Nuttha, Macedo, Etienne, Maiwall, Rakhi, Marciano, Sebastian, Pichler, Raimund H., Ronco, Claudio, Tandon, Puneeta, Velez, Juan-Carlos Q., Mehta, Ravindra L., and Durand, François

Published
2024
Full Text
View/download PDF

7. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US

Author

Patidar, Kavish R., Belcher, Justin M., Regner, Kevin R., St. Hillien, Shelsea A., Simonetto, Douglas A., Asrani, Sumeet K., Neyra, Javier A., Sharma, Pratima, Velez, Juan Carlos Q., Wadei, Hani, Nadim, Mitra K., Chung, Raymond T., Seethapathy, Ritu, Parada, Xavier Vela, Ouyang, Tianqi, Ufere, Nneka N., Robinson, Jevon E., McLean Diaz, Paige, Wilechansky, Robert M., Przybyszewski, Eric M., Smith, Thomas N., Ali, Arzina Aziz, Orman, Eric S., Schulz, Philipp, Siddiqui, Salaah M., Shabbir, Rehma, Liu, Lucas J., Cama-Olivares, Augusto, Flannery, Alexander H., Baker, Megan L., Gunasekaran, Deepthi, Aswine, Adeline, Issa, Rafik, Li, Jay, Verma, Shreya, Chalmers, Dustin, Varghese, Vipin, Lam, Walter, Mohamed, Muner, Kovacic, Rosemary, Gaddy, Anna, Attieh, Rose Mary, Cortes, Pedro, Semnani, Sahar, Wang, Lin, Khemichian, Saro, and Allegretti, Andrew S.

Published
2023
Full Text
View/download PDF

8. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension

Author

Boike, Justin R., Thornburg, Bartley G., Asrani, Sumeet K., Fallon, Michael B., Fortune, Brett E., Izzy, Manhal J., Verna, Elizabeth C., Abraldes, Juan G., Allegretti, Andrew S., Bajaj, Jasmohan S., Biggins, Scott W., Darcy, Michael D., Farr, Maryjane A., Farsad, Khashayar, Garcia-Tsao, Guadalupe, Hall, Shelley A., Jadlowiec, Caroline C., Krowka, Michael J., Laberge, Jeanne, Lee, Edward W., Mulligan, David C., Nadim, Mitra K., Northup, Patrick G., Salem, Riad, Shatzel, Joseph J., Shaw, Cathryn J., Simonetto, Douglas A., Susman, Jonathan, Kolli, K. Pallav, and VanWagner, Lisa B.

Published
2022
Full Text
View/download PDF

13. SAT-082 A phase 2 study of OCE-205, a novel, selective vasopressin receptor mixed agonist-antagonist: positive proof-of-concept established in subjects with cirrhosis and hepatorenal syndromeacute kidney injury (HRS-AKI)

Author

Allegretti, Andrew S., primary, Bajaj, Jasmohan, additional, Bari, Khurram, additional, Brown, Robert S., additional, Cullaro, Giuseppe, additional, Ganger, Daniel, additional, Hassanein, Tarek, additional, Kemmer, Nyingi, additional, Khemichian, Saro, additional, Yien Kwo, Paul, additional, Lim, Nicholas, additional, Naqvi, Hasan, additional, Patidar, Kavish, additional, Pyrsopoulos, Nikolaos T., additional, Rahimi, Robert S., additional, Rockey, Don, additional, Sanyal, Arun J., additional, Shetty, Kirti, additional, Simonetto, Douglas, additional, Stein, Lance, additional, Vargas, Hugo, additional, Zamor, Philippe, additional, Bernstein, David, additional, Kjems, Lise, additional, Lam, Jason, additional, Reid, Susan, additional, and Wong, Florence, additional

Published
2024
Full Text
View/download PDF

14. OS-038-YI Real-world practice patterns on the use of terlipressin in patients with cirrhosis and acute kidney injury-results from the ICA-GLOBAL AKI study

Author

Ma, Ann Thu, primary, Juanola, Adrià, additional, Patidar, Kavish, additional, Barone, Anna, additional, Incicco, Simone, additional, Kulkarni, Anand, additional, Pérez-Hernández, José Luis, additional, Wentworth, Brian, additional, Asrani, Sumeet, additional, Alessandria, Carlo, additional, Abdelkader, Nadia Abdelaaty, additional, Wong, Yu Jun, additional, Xie, Qing, additional, Pyrsopoulos, Nikolaos T., additional, Kim, Sung-Eun, additional, Fouad, Yasser, additional, Torre, Aldo, additional, Reyes, Eira Cerda, additional, Diaz-Ferrer, Javier, additional, Maiwall, Rakhi, additional, Simonetto, Douglas, additional, Papp, Maria, additional, Orman, Eric, additional, Perricone, Giovanni, additional, Solé, Cristina, additional, Lange, Christian M., additional, Farias, Alberto, additional, Pereira, Gustavo, additional, Gadano, Adrian, additional, Caraceni, Paolo, additional, Thévenot, Thierry, additional, Verma, Nipun, additional, Kim, Jeong Han, additional, Vorobioff, Julio D., additional, Cordova-Gallardo, Jacqueline, additional, Ivashkin, Vladimir, additional, Roblero, Juan Pablo, additional, Maan, Raoel, additional, Toledo, Claudio, additional, Riggio, Oliviero, additional, Fassio, Eduardo, additional, Marino, Mónica, additional, Nabilou, Puria, additional, Vargas, Victor, additional, Merli, Manuela, additional, Goncalves, Luciana Lofego, additional, Rabinowich, Liane, additional, Krag, Aleksander, additional, Balcar, Lorenz, additional, Montes, Pedro, additional, Mattos, Angelo Z., additional, Bruns, Tony, additional, Nur, Abdulsemed Mohammed, additional, Laleman, Wim, additional, Estupiñan, Enrique Carrera, additional, Cabrera, Maria Cecilia, additional, Girala, Marcos, additional, Samant, Hrishikesh, additional, Raevens, Sarah, additional, Madaleno, Joao, additional, Kim, W. Ray, additional, Arab, Juan Pablo, additional, Presa, José, additional, Ferreira, Carlos Noronha, additional, Galante, Antonio, additional, Roux, Olivier, additional, Allegretti, Andrew S., additional, Takkenberg, R. Bart, additional, Harputluoglu, Murat, additional, Marciano, Sebastián, additional, Sarin, Shiv Kumar, additional, Ginès, Pere, additional, Angeli, Paolo, additional, Solà, Elsa, additional, and Piano, Salvatore, additional

Published
2024
Full Text
View/download PDF

21. Filter clotting with continuous renal replacement therapy in COVID-19

Author

Endres, Paul, Rosovsky, Rachel, Zhao, Sophia, Krinsky, Scott, Percy, Shananssa, Kamal, Omer, Roberts, Russel J., Lopez, Natasha, Sise, Meghan E., Steele, David J. R., Lundquist, Andrew L., Rhee, Eugene P., Hibbert, Kathryn A., Hardin, C. Corey, Mc Causland, Finnian R., Czarnecki, Peter G., Mutter, Walter, Tolkoff-Rubin, Nina, and Allegretti, Andrew S.

Published
2021
Full Text
View/download PDF

22. Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium.

Author

Ma, Ann T., Allegretti, Andrew S., Cullaro, Giuseppe, Ouyang, Tianqui, Asrani, Sumeet K., Chung, Raymond T., Przybyszewski, Eric M., Wilechansky, Robert M., Robinson, Jevon E., Sharma, Pratima, Simonetto, Douglas A., Jalal, Prasun, Orman, Eric S., Wadei, Hani M., St. Hillien, Shelsea A., Saly, Danielle, Ufere, Nneka N., Dageforde, Leigh Anne, Regner, Kevin R., and Belcher, Justin M.

Subjects
*ACUTE kidney failure, *HEPATORENAL syndrome, *RENAL replacement therapy, *ALCOHOLISM, *CIRRHOSIS of the liver
Abstract

Summary: Background & Aims: The development of acute kidney injury (AKI) in the setting of alcohol‐associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown. Methods: Retrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non‐AH groups. Results: A total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End‐stage Liver Disease‐Sodium (MELD‐Na) scores on admission. AKI phenotypes significantly differed between groups (p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90‐day cumulative incidence of death (45% [95% CI: 39%–51%] vs. 38% [95% CI: 35%–40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90‐day mortality was higher for AH (sHR: 1.24 [95% CI: 1.03–1.50], p = 0.024), but was not significant when adjusting for MELD‐Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90‐day mortality (sHR: 1.82 [95% CI: 1.16–2.86], p = 0.009). Conclusions: Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90‐day mortality than those without AH, but this may have been driven by higher MELD‐Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Reduced guanidinoacetate in plasma of patients with autosomal dominant Fanconi syndrome due to heterozygous P341L GATM variant and study of organoids towards treatment.

Author

Portales‐Castillo, Ignacio, Singal, Rhea, Ambrose, Anastasia, Song, Jong Hee, Son, Minsoo, Goo, Young Ah., Zhou, Wen, Traum, Avram Z., Coler‐Reilly, Ariella, Humphreys, Benjamin D., Civitelli, Roberto, Jüppner, Harald, Lundquist, Andrew L., Seres, Peter, Allegretti, Andrew S., and Mercimek‐Andrews, Saadet

Published
2024
Full Text
View/download PDF

24. CONTROVERSIES IN LIVER TRANSPLANTATION CORNER.

Author

Przybyszewski, Eric M., Wilechansky, Robert M., Diaz, Paige McLean, Allegretti, Andrew S., VanWagner, Lisa B., Cullaro, Giuseppe, Levitsky, Josh, Ginès, Pere, Piano, Salvatore, Asrani, Sumeet K., and Patidar, Kavish R.

Published
2024
Full Text
View/download PDF

28. Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice

Author

Battistone, Maria Agustina, Mendelsohn, Alexandra C., Spallanzani, Raul German, Allegretti, Andrew S., Liberman, Rachel N., Sesma, Juliana, Kalim, Sahir, Wall, Susan M., Bonventre, Joseph V., Lazarowski, Eduardo R., Brown, Dennis, and Breton, Sylvie

Subjects
Glucose, Cardiac patients, Kidney diseases -- Prevention, Health care industry
Abstract

Ischemic acute kidney injury (AKI), a complication that frequently occurs in hospital settings, is often associated with hemodynamic compromise, sepsis, cardiac surgery, or exposure to nephrotoxins. Here, using a murine renal ischemia/ reperfusion injury (IRI) model, we show that intercalated cells (ICs) rapidly adopted a proinflammatory phenotype after IRI. Wwe demonstrate that during the early phase of AKI either blockade of the proinflammatory P2Y14 receptor located on the apical membrane of ICs or ablation of the gene encoding the P2Y14 receptor in ICs (a) inhibited IRI-induced increase of chemokine expression in ICs, (b) reduced neutrophil and monocyte renal infiltration, (c) reduced the extent of kidney dysfunction, and (d) attenuated proximal tubule damage. These observations indicate that the P2Y14 receptor participates in the very first inflammatory steps associated with ischemic AKI. In addition, we show that the concentration of the P2Y14 receptor ligand UDP-glucose (UDP-Glc) was higher in urine samples from intensive care unit patients who developed AKI compared with patients without AKI. In particular, we observed a strong correlation between UDP-Glc concentration and the development of AKI in cardiac surgery patients. Our study identifies the UDP-Glc/P2Y14 receptor axis as a potential target for the prevention and/or attenuation of ischemic AKI., Introduction Acute kidney injury (AKI) is a frequent medical complication seen in hospitalized patients. It is associated with an increased length of hospital stay, the development of chronic kidney disease, [...]

Published
2020
Full Text
View/download PDF

30. Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group

Author

Verberne, Wouter R., Das-Gupta, Zofia, Allegretti, Andrew S., Bart, Hans A.J., van Biesen, Wim, García-García, Guillermo, Gibbons, Elizabeth, Parra, Eduardo, Hemmelder, Marc H., Jager, Kitty J., Ketteler, Markus, Roberts, Charlotte, Al Rohani, Muhamed, Salt, Matthew J., Stopper, Andrea, Terkivatan, Türkan, Tuttle, Katherine R., Yang, Chih-Wei, Wheeler, David C., and Bos, Willem Jan W.

Published
2019
Full Text
View/download PDF

32. Severe Hyponatremia Correction, Mortality, and Central Pontine Myelinolysis

Author

Seethapathy, Harish, primary, Zhao, Sophia, additional, Ouyang, Tianqi, additional, Passos, Christie, additional, Sarang, Adviti, additional, Cheung, Pui W., additional, Waikar, Sushrut S., additional, Steele, David J.R., additional, Kalim, Sahir, additional, Allegretti, Andrew S., additional, Ayus, Juan Carlos, additional, and Nigwekar, Sagar U., additional

Published
2023
Full Text
View/download PDF

36. Vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration.

Author

Lopez, Natasha D., Griggs, Michael, Sin, Jonathan H., Roberts, Russel J., and Allegretti, Andrew S.

Subjects
VANCOMYCIN, DRUG monitoring, BLOOD filtration, PHARMACOKINETICS, RENAL replacement therapy
Abstract

Introduction: Vancomycin pharmacokinetics are affected by renal replacement therapy and physiologic changes in critically ill patients. Literature regarding vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration (AVVH), a form of prolonged intermittent renal replacement therapy, is limited. Objective: To describe the removal and pharmacokinetics of vancomycin during AVVH. Methods: Eighteen critically ill adults receiving vancomycin and AVVH were included. Vancomycin serum concentrations were obtained within 4 h before and 2–6 h after the AVVH session. Patients' serum concentrations were plotted against time, and individual pharmacokinetic parameters were determined by a one‐compartmental analysis. Continuous data are reported as a median (interquartile range [IQR]) and categorical data as a percentage. Results: The median AVVH effluent rate was 39.3 mL/kg/h (IQR 35.5–48 mL/kg/h) for a duration of 9 h (IQR 8–9.75 h). AVVH decreased vancomycin concentrations by 29.8% (IQR 24.9%–35.9%), at a rate of 3.4% per hour (IQR 3.1%–4.3% per hour) of AVVH. The vancomycin elimination rate constant and half‐life were 0.039 h−1 (IQR 0.036–0.053 h−1) and 17.6 h (IQR 13.1–18.8 h), respectively. The area under the curve during AVVH was 171.7 mg*h/L (IQR 149.1–190 mg*h/L). The volume of distribution in 10 patients was 1 L/kg (IQR 0.73–1.1 L/kg). After AVVH, vancomycin 1000 mg (IQR 750–1000 mg) was needed to maintain a serum trough concentration ≥15 mg/L. Conclusion: Vancomycin is significantly removed by AVVH, which requires supplemental dosing after completion of the AVVH session to maintain desired serum concentrations. Therapeutic drug monitoring of vancomycin serum concentrations is recommended for patients undergoing AVVH. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial

Author

Pose, Elisa, primary, Jiménez, César, additional, Zaccherini, Giacomo, additional, Campion, Daniela, additional, Piano, Salvatore, additional, Uschner, Frank Erhard, additional, de Wit, Koos, additional, Roux, Olivier, additional, Gananandan, Kohilan, additional, Laleman, Wim, additional, Solé, Cristina, additional, Alonso, Sonia, additional, Cuyas, Berta, additional, Ariza, Xavier, additional, Juanola, Adria, additional, Ma, Ann T, additional, Napoleone, Laura, additional, Gratacos, Jordi, additional, Tonon, Marta, additional, Pompili, Enrico, additional, Sánchez-Delgado, Jordi, additional, Carol, Marta, additional, Perez, Martina, additional, Fabrellas, Núria, additional, Pich, Judit, additional, Martell, Claudia, additional, Casanovas, Georgina, additional, Domenech, Gemma, additional, Torres, Ferran, additional, Manuel, Víctor, additional, Blasco, Vargas, additional, Caraceni, Paolo, additional, Alessandria, Carlo, additional, Angeli, Paolo, additional, Trebicka, Jonel, additional, Beuers, Ulrich, additional, Francoz, Claire, additional, Mookerjee, Raj, additional, Bañares, Rafael, additional, Soriano, German, additional, Hernaez, Ruben, additional, Allegretti, Andrew S., additional, Morales-Ruiz, Manuel, additional, Serra, Miquel, additional, Watson, Hugh, additional, Abraldes, Juan G, additional, Kamath, Patrick S., additional, and Ginès, Pere, additional

Published
2023
Full Text
View/download PDF

42. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis

Author

Juanola, Adrià, Ma, Ann Thu, de Wit, Koos, Gananandan, Kohilan, Roux, Olivier, Zaccherini, Giacomo, Jiménez, César, Tonon, Marta, Solé, Cristina, Villaseca, Clara, Uschner, Frank E, Graupera, Isabel, Pose, Elisa, Moreta, Maria José, Campion, Daniela, Beuers, Ulrich, Mookerjee, Rajeshawar P, Francoz, Claire, Durand, Francois, Vargas, Victor, Piano, Salvatore, Alonso, Sonia, Trebicka, Jonel, Laleman, Wim, Asrani, Sumeet K, Soriano, German, Alessandria, Carlo, Serra-Burriel, Miquel, Morales-Ruiz, Manuel, Torres, Ferran, Allegretti, Andrew S, Krag, Aleksander, Caraceni, Paolo, Watson, Hugh, Abraldes, Juan G, Solà, Elsa, Kamath, Patrick S, Hernaez, Ruben, and Ginès, Pere

Abstract

BackgroundPatients with decompensated cirrhosis experience high mortality rates. Current prognostic scores, including the model for end-stage liver disease (MELD), may underperform in settings other than in those they were initially developed. Novel biomarkers have been proposed to improve prognostication accuracy and even to predict development of complications.MethodsWe performed a systematic review and meta-analysis on novel urine and blood biomarkers and their ability to predict 90-day mortality in patients with decompensated cirrhosis. Secondary outcomes included 28-day and 1-year mortality, and development of acute-on-chronic liver failure, acute kidney injury and other complications. To overcome differences in units, temporal changes in assays and reporting heterogeneity, we used the ratio of means (RoM) as measure of association for assessing strength in predicting outcomes. An RoM>1 implies that the mean biomarker level is higher in those that develop the outcome than in those that do not.ResultsOf 6629 unique references, 103 were included, reporting on 29 different biomarkers, with a total of 31 362 biomarker patients. Most studies were prospective cohorts of hospitalised patients (median Child-Pugh-Turcotte score of 9 and MELD score of 18). The pooled 90-day mortality rate was 0.27 (95% CI 0.24 to 0.29). The RoM for predicting 90-day mortality was highest for interleukin 6 (IL-6) (2.56, 95% CI 2.39 to 2.74), followed by urinary neutrophil gelatinase-associated lipocalin (uNGAL) (2.42, 95% CI 2.20 to 2.66) and copeptin (2.33, 95% CI 2.17 to 2.50). These RoMs were all higher than for MELD (1.44, 95% CI 1.42 to 1.46).ConclusionNovel biomarkers, including IL-6, uNGAL and copeptin, can probably improve prognostication of patients with decompensated cirrhosis compared with MELD alone.

Published
2024
Full Text
View/download PDF

43. Longer time to recovery from acute kidney injury is associated with major adverse kidney events in patients with cirrhosis

Author

Patidar, Kavish R., primary, Naved, Mobasshir A., additional, Kabir, Shaowli, additional, Grama, Ananth, additional, Allegretti, Andrew S., additional, Cullaro, Giuseppe, additional, Asrani, Sumeet K., additional, Worden, Astin, additional, Desai, Archita P., additional, Ghabril, Marwan S., additional, Nephew, Lauren D., additional, and Orman, Eric S., additional

Published
2023
Full Text
View/download PDF

45. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1

Author

Velez, Juan Carlos Q., primary, Karakala, Nithin, additional, Tayebi, Kasra, additional, Wickman, Terrance J., additional, Mohamed, Muner M. B., additional, Kovacic, Rosemary A., additional, Therapondos, George, additional, Kanduri, Swetha R., additional, Allegretti, Andrew S., additional, Belcher, Justin M., additional, Regner, Kevin R., additional, and Wentowski, Cathy, additional

Published
2023
Full Text
View/download PDF

50. Additional file 1 of The association between olfactory and gustatory dysfunction and chronic kidney disease

Author

Chewcharat, Api, Phipps, Elizabeth A., Bhatia, Khushboo, Kalim, Sahir, Allegretti, Andrew S., Sise, Meghan E., P��unescu, Teodor G., Seethapathy, Rituvanthikaa, and Nigwekar, Sagar U.

Subjects
urologic and male genital diseases, female genital diseases and pregnancy complications
Abstract

Additional file 1: Supplementary Table 1. The association between expanded CKD and olfactory and gustatory dysfunction. Supplementary Table 2a. The association between olfactory dysfunction and nutritional markers among expanded CKD. Supplementary Table 2b. The association between gustatory dysfunction and nutritional markers among expanded CKD.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results